SGS Increases Biopharma Characterization Capabilities

Aug 28, 2018
By BioPharm International Editors

SGS announced on Aug. 28, 2018 that the company is expanding its biopharmaceutical testing capabilities in Geneva, Switzerland with the addition of a 200-sq.-m laboratory for early and late phase of biopharmaceutical characterization.

Scheduled to open by the end of the third quarter of 2018, the new laboratory will provide services for high-order structure analysis of biologics, including circular dichroism (CD), Fourier-transform infrared spectroscopy (FTIR), extrinsic and intrinsic fluorescence, analytical ultracentrifugation (SV-AUC), size exclusion chromatography with multi-angle light scattering (SEC-MALS), dynamic light scattering (DLS) and differential scanning calorimetry (DSC).

When complete, the new laboratory will enable the Geneva facility—which opened in 1991 and is cGMP certified, GLP compliant, and FDA inspected—to offer ICH Q6B physico-chemical characterization of biological products, the company reported in a press announcement.

Source: SGS


lorem ipsum